10th Medical Innovations Summit | The Royal Society of Medicine | London | Saturday 18th April 2015

Staphefektsustainable antibacterial therapy with endolysins

Mark Offerhaus, CEO MicreosBjorn Herpers, Clinical microbiologist

©2015 Micreos

“We believe the environmental hit in AD relates to staphylococci and their biofilms,

which occlude sweat ducts [...leading…] to inflammation and pruritis.”

(Allen, JAMA Dermatol. 2014)

“Staphylococcus aureus […] produces pain

by directly activating sensory neurons that modulate inflammation.”

(Chiu, Nature 2013)

“The proportion of […] particularly S. aureus was greater during disease flares

[…] and correlated with worsened disease severity.”

(Kong, Genome Res. 2012)

“Antibiotic resistance is one of the most pressing

public health issues facing the world today.”

(President Obama)

“Antimicrobial resistance requires action across

all government sectors and society... People with

MRSA are 64% more likely to die from infection

than people with a non-resistant form...

The problem is so serious that it threatens the

achievements of modern medicine”

(World Health Organization)

“Superbugs risk taking us back

to the dark ages”

(Prime Minister Cameron)

Lysis of bacterial cell by endolysins

Critical step in replication cycle

Resistance in this step unlikely

Endolysins (Staphefekt) lyse cell from outside

No phage needed, only protein

0%

25%

50%

75%

100%

0 20 40 60

Decre

ase

in o

pti

cal

den

sit

y

t (minutes)

S. epidermidis

MSSA

MRSA

0

1000

2000

3000

4000

5000

0 5 10 15 20

MIC

Number of exposition cycles

Lysostaphin

Mupirocin

Staphefekt

Systemic Infection

Sepsis

Systemic Infection

Sepsis

Skin Colonization

Irritation

Inflammation

Local Infection

Skin Colonization

Irritation

Inflammation

Local Infection

Systemic Infection

Sepsis

Bacteria interact with the human body throughout the Colonisation Infection Continuum. Every alteration at the early stages,

either the emergence of resistance or the suppression of pathogens, has its effect downstream.

Eradication of carriership S. aureus from the skin Skin Colonization

Staphefekt - Carriership

Inflammation

Staphefekt - Acne

Skin Colonization

IrritationAcne

Before Gladskin

Proven S. aureus

After Gladskin

Inflammation

Staphefekt - Acne

Acne

Skin Colonization

Irritation

0

0.5

1

1.5

2

2.5

Acne - severity

Comedones*

Pain*

Cysts*

Papules*

Pustules

(n = 59, mean therapy 37 days, *p<0.02)

Prof. S. Pasmans, J. Totté, Erasmus MC Rotterdam

manuscript submitted

Decreased severity after Staphefekt

Inflammation

0.5

0.75

1

1.25

1.5

1.75

2

Staphefekt - Rosacea

Skin Colonization

Irritation

Rosacea - severity

Dry skin*

Burning

Papules

Persistent

erythema

Edema

(n = 112, mean therapy 37 days, *p<0.01)

Itch* Flushing

Teleangiectasia

Eye symptoms

Pustules*

Suggests role for S. aureus

in inflammatory symptoms

Inflammatory Vascular

Rosacea

Prof. S. Pasmans, J. Totté, Erasmus MC Rotterdam

manuscript submitted

Decreased severity after Staphefekt

Staphefekt - Dermatitis / Eczema

Skin Colonization

Irritation

Inflammation

(Kong, Genome Res. 2012)

Eczema / Dermatitis: S. aureus precedes eczema flare

Staphefekt - Dermatitis / Eczema

S. aureus related Dermatitis / Eczema

Skin Colonization

Irritation

Inflammation

Staphefekt - Furunculosis

Furunculosis

Skin Colonization

Irritation

Inflammation

Local Infection

Before Gladskin

Proven S. aureus

2 weeks 4 weeks

Staphefekt - Furunculosis

After StaphefektBefore Staphefekt

Staphefekt – Prosthetic joint infections

Prosthetic Joint Infections

Skin Colonization

Irritation

Inflammation

Local Infection

Systemic Infection

Staphefekt SA.100

t (minutes)

Decre

ase i

n o

pti

cal

den

sit

y

Staphefekt SA.100 Staphefekt SA.200

t (minutes)

Decre

ase i

n o

pti

cal

den

sit

y

Decre

ase i

n o

pti

cal

den

sit

y

t (minutes)

Staphefekt – 2nd generation

Killing all staphylococci in biofilms:

Necessary for Prosthetic Joint Infections

Selectively killing Staphylococcus aureus

Side effects

Not selective

Resistance induction

Skin Colonization

Irritation

Inflammation

Local Infection

Systemic Infection

Sepsis

Antibiotics

Use is limited

in time & indication

Colonization Infection Continuum

Skin Colonization

Irritation

Inflammation

Local Infection

Systemic Infection

Sepsis

Selective

No resistance induction

Staphefekt / Endolysins

Suitable for long term

suppression therapy

and prophylaxis

ETH Zurich – Technical Partner

Prof. M. Loessner (CTO)

Dr. F. Eichenseher

“If you’re not prepared to be

wrong, you’ll never come up with

something original”

(Ken Robinson - How Schools Kill Creativity)

S.O.S. programme – StaphefektTM made available for free for research purposes

10th Medical Innovations Summit | The Royal Society of Medicine | London | Saturday 18th April 2015

Thank you

Mark Offerhaus, CEO MicreosBjorn Herpers, Clinical microbiologist

info@micreos.com - www.micreos.com